相关实验视频

Updated: Jan 10, 2026

Murine Fecal Isolation and Microbiota Transplantation

Murine Fecal Isolation and Microbiota Transplantation

Published on: May 26, 2023

肠道微生物群衍生代谢物和心血管疾病:专注于三甲基胺-N-氧化物

Mengxue He¹, Chin Ping Tan², Yuanfa Liu^3,1

¹State Key Laboratory of Food Science and Resources, School of Food Science and Technology, National Engineering Research Center for Functional Food, National Engineering Laboratory for Cereal Fermentation Technology, Collaborative Innovation Center of Food Safety and Quality Control in Jiangsu Province, Jiangnan University, 214122 Wuxi, China.

Journal of agricultural and food chemistry

|November 20, 2025

概括

三甲基胺-N-氧化物 (TMAO) 是肠道微生物的代谢物,通过促进炎症和血栓形成,驱动动动脉硬化. 通过饮食或药物减少TMAO可能提供新的心血管疾病预防策略.

科学领域:

心血管医学心血管医学
微生物组研究微生物组研究
代谢学代谢学代谢学

背景情况:

心血管疾病 (CVD) 是全球领先的健康问题.
肠道微生物群的代谢物,特别是三甲基胺-N-氧化物 (TMAO),越来越多地与心血管疾病的发病有关.
TMAO被公认为是一种益动脉动脉代谢物和一个独立的心血管疾病风险因素.

研究的目的:

审查目前对TMAO在动脉样硬化斑块发育中的作用的理解.
探索TMAO对炎症,免疫反应,脂质代谢,内皮功能和血栓形成的影响.
评估针对TMAO进行心血管风险降低的治疗策略.

主要方法:

文献综述综合了关于TMAO和动脉样硬化的当前研究.
对TMAO在动脉生成中的分子机制的分析.
对饮食,微生物群和药物干预措施的评估.

主要成果:

通过激活炎症细胞和改变巨细胞极化,TMAO促进动脉样硬化,导致泡细胞的形成.
TMAO破坏脂质代谢,损害逆胆固醇运输,并损害内皮完整性.
TMAO增强了血小板的高反应性,增加了血栓形成的潜力.

结论:

TMAO是动脉样硬化的关键调解者,通过多种途径起作用.
TMAO作为潜在的诊断生物标志物和心血管疾病的治疗点.
微生物群导向疗法通过调节TMAO水平来降低心血管风险,显示出有希望的结果.

关键词:

心血管疾病心血管疾病我们的肠道微生物群.治疗策略治疗策略三甲基胺-N-氧化物

更多相关视频

An In Vivo Method for Evaluating the Gut-Blood Barrier and Liver Metabolism of Microbiota Products

An In Vivo Method for Evaluating the Gut-Blood Barrier and Liver Metabolism of Microbiota Products

Published on: October 20, 2018

Intracerebroventricular Delivery of Gut-Derived Microbial Metabolites in Freely Moving Mice

Intracerebroventricular Delivery of Gut-Derived Microbial Metabolites in Freely Moving Mice

Published on: June 2, 2022

相关概念视频

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Psychoneuroimmunology: Cardiovascular Disease

Psychoneuroimmunology: Cardiovascular Disease

Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...